Loading...
Loading...
DAWN| Name | Value |
|---|---|
| Revenues | 93.8M |
| Cost of Revenue | 1.6M |
| Gross Profit | 92.2M |
| Operating Expense | 62.5M |
| Operating I/L | 29.6M |
| Other Income/Expense | 6.5M |
| Interest Income | 5.3M |
| Pretax | 36.2M |
| Income Tax Expense | -0.9M |
| Net Income/Loss | 37.0M |
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing targeted therapies for genetically defined cancers. Its lead product candidate, DAY101, is an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor currently in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.
